Janux Therapeutics, Inc. (JANX) Financial Ratios
7 years of historical data (2019–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↓
0.92
↓-49% vs avg
5yr avg: 1.80
30Y Low0.9·High2.8
ROE
↑
-11.5%
↓+25% vs avg
5yr avg: -15.2%
30Y Low-19%·High-10%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
JANX Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Janux Therapeutics, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Market Cap | $867M | $855M | $2.9B | $472M | $546M | $814M | — | — |
| Enterprise Value | $837M | $825M | $2.5B | $478M | $520M | $778M | — | — |
| P/E Ratio → | -7.77 | — | — | — | — | — | — | — |
| P/S Ratio | 86.72 | 85.51 | 271.80 | 58.43 | 63.42 | 223.74 | — | — |
| P/B Ratio | 0.92 | 0.89 | 2.81 | 1.37 | 1.70 | 2.22 | — | — |
| P/FCF | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
JANX EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 82.49 | 233.31 | 59.09 | 60.38 | 214.01 | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — |
JANX Profitability
Margins and return-on-capital ratios measuring operating efficiency
Janux Therapeutics, Inc. earns an operating margin of -1576.7%. Operating margins have compressed from -902.9% to -1576.7% over the past 3 years, signaling potential cost pressures or competitive headwinds. A negative ROE of -11.5% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 79.7% | 79.7% | 80.5% | 75.8% | 90.2% | 100.0% | — | — |
| Operating Margin | -1576.7% | -1576.7% | -933.6% | -902.9% | -779.0% | -905.4% | — | — |
| Net Profit Margin | -1136.3% | -1136.3% | -651.6% | -721.2% | -732.2% | -898.3% | — | — |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| ROE | -11.5% | -11.5% | -10.1% | -17.5% | -18.4% | -18.6% | — | — |
| ROA | -11.0% | -11.0% | -9.6% | -15.7% | -17.0% | -16.5% | -80.3% | -624.0% |
| ROIC | -15.3% | -15.3% | -15.4% | -17.0% | -16.1% | -16.0% | — | — |
| ROCE | -15.6% | -15.6% | -14.0% | -20.4% | -18.8% | -17.3% | -106.6% | — |
JANX Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $52M exceeds total debt of $22M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.02 | 0.02 | 0.02 | 0.07 | 0.08 | 0.00 | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.03 | -0.40 | 0.02 | -0.08 | -0.10 | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | — | — | -31.93 | -16.18 |
Net cash position: cash ($52M) exceeds total debt ($22M)
JANX Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Janux Therapeutics, Inc.'s current ratio of 39.04x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has improved from 26.80x to 39.04x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Current Ratio | 39.04 | 39.04 | 59.21 | 26.80 | 20.14 | 29.46 | 5.05 | 0.14 |
| Quick Ratio | 39.04 | 39.04 | 59.21 | 26.80 | 20.18 | 29.46 | 5.05 | 0.14 |
| Cash Ratio | 38.67 | 38.67 | 58.72 | 26.40 | 19.81 | 29.30 | 2.46 | 0.14 |
| Asset Turnover | — | 0.01 | 0.01 | 0.02 | 0.02 | 0.01 | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | 234.62 | 185.50 | — | 29.67 | — | — | — |
JANX Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Janux Therapeutics, Inc. returns 0.0% to shareholders annually primarily through share buybacks.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $62M | $54M | $44M | $41M | $41M | $42M | $42M |
Peer Comparison
Compare JANX with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 JANXYou | $867M | -7.8 | — | — | 79.7% | -1576.7% | -11.5% | -15.3% | — |
 IMVT | $7B | -12.8 | — | — | — | — | -64.8% | — | — |
 KYMR | $7B | -24.5 | — | — | 100.0% | -891.3% | -25.8% | -24.9% | — |
 RCUS | $2B | -7.4 | — | — | 96.0% | -156.3% | -63.3% | -64.1% | — |
 TNGX | $3B | -32.1 | — | — | 96.3% | -178.4% | -37.2% | -38.5% | — |
 RVMD | $35B | -27.4 | — | — | — | — | -58.1% | -54.3% | — |
 XNCR | $927M | -10.2 | — | — | 91.6% | -141.4% | -14.0% | -16.3% | — |
 MGNX | $263M | -3.5 | — | — | 71.1% | -48.7% | -86.9% | -144.1% | — |
 AGEN | $125M | -882.4 | — | — | 29.6% | -18.0% | — | — | — |
 ALKS | $7B | 31.5 | 22.9 | 15.6 | 86.7% | 17.2% | 14.7% | 18.9% | 0.2 |
 FATE | $244M | -1.8 | — | — | -94.1% | -2222.4% | -51.8% | -36.5% | — |
| Healthcare Median | — | 22.1 | 14.2 | 18.5 | 63.9% | -4.3% | -32.6% | -11.6% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 7 years · Updated daily
Consensus-Based Analysis Tools
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare
JANX — Frequently Asked Questions
Quick answers to the most common questions about buying JANX stock.
What is Janux Therapeutics, Inc.'s P/E ratio?
Janux Therapeutics, Inc.'s current P/E ratio is -7.8x. This places it at the 50th percentile of its historical range.
What is Janux Therapeutics, Inc.'s ROE?
Janux Therapeutics, Inc.'s return on equity (ROE) is -11.5%. The historical average is -15.2%.
Is JANX stock overvalued?
Based on historical data, Janux Therapeutics, Inc. is trading at a P/E of -7.8x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are Janux Therapeutics, Inc.'s profit margins?
Janux Therapeutics, Inc. has 79.7% gross margin and -1576.7% operating margin.